Clinical Trial Update: GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）

View source ↗

Summary

A clinical trial (BTC-IM-1) is evaluating the combination of GemCis (gemcitabine + cisplatin) with a PD-1/PD-L1 inhibitor in advanced biliary tract cancer; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• GemCis (gemcitabine + cisplatin)
• Gemcitabine (Gemcitabine)
• PD-1/PD-L1 inhibitor

Snippet

Sponsor: Fudan University | Conditions: Advanced Biliary Tract Cancer | Status: RECRUITING